{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":44,"n_cols":5,"rows_kept":44,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[12,2,12,3],[13,2,13,3],[17,2,17,3],[20,2,20,3],[20,4,20,5],[21,2,21,3],[21,4,21,5],[22,2,22,3],[22,4,22,5],[23,2,23,3],[25,2,25,3],[28,2,28,3],[29,2,29,3],[30,2,30,3],[31,2,31,3],[32,2,32,3],[33,2,33,3],[37,2,37,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910783223003321"]
[null,null,"Autore",null,"Cardone Fabio"]
[null,null,"Titolo",null,"Energy and geometry [[electronic resource] ] : an introduction to deformed special relativity / / Fabio Cardone, Roberto Mignani"]
[null,null,"Pubbl/distr/stampa",null,"River Edge, N.J., : World Scientific, 2004"]
[null,null,"ISBN",null,"1-281-87695-X"]
[{"$nulls":4},"9786611876951"]
[{"$nulls":4},"981-256-537-X"]
[null,null,"Descrizione fisica",null,"1 online resource (161 p.)"]
[null,null,"Collana",null,"World Scientific series in contemporary chemical physics ; ; v. 22"]
[null,null,"Disciplina",null,"530.11"]
[null,null,"Soggetti",null,"Special relativity (Physics)"]
[{"$nulls":4},"Generalized spaces"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Dedication; Preface; Contents; I Generalizing Special Relativity; 1 An Axiomatic View to Special Relativity; 2 Deformed Minkowski Space-Time; 3 Description of Interactions by Energy-Dependent Metrics; II Relativity in a Deformed Space-Time; 4 Generalized Principle of Relativity and Lorentz Transformations; 5 Relativistic Kinematics in a Deformed Minkowski Space; 6 Wave Propagation in a Deformed Space-Time; III Metric Description of Fundamental Interactions; 7 Nonlocal Effects in Electromagnetic Interaction; 8 Energy-Dependent Metric for Gravitation; 9 Weak Interaction; 10 Strong Interaction"]
[{"$nulls":4},"11 Metrics of InteractionsIV Breakdown of Local Lorentz Invariance; 12 Experimental Tests of Local Lorentz Invariance; 13 A New Electromagnetic Test of LLI; 14 The Gravitational Mass of Electron from Geometry; 15 Toward the Fifth Dimension; References; Index"]
[null,null,null,"Sommario/riassunto","Special Relativity (SR) is essentially grounded on the properties of space-time, i.e. isotropy of space and homogeneity of space and time (as a consequence of the equivalence of inertial frames) and on the Galilei principle of relativity."]
[null,"2.","Record Nr.",null,"UNINA9910808374903321"]
[null,null,"Autore",null,"Lednicer Daniel"]
[null,null,"Titolo",null,"Antineoplastic drugs : organic synthesis / / Daniel Lednicer"]
[null,null,"Pubbl/distr/stampa",null,"Chichester, England : , : Wiley, , 2015"]
[{"$nulls":4},"©2015"]
[null,null,"ISBN",null,"1-118-89256-9"]
[{"$nulls":4},"1-118-89255-0"]
[{"$nulls":4},"1-118-89257-7"]
[null,null,"Descrizione fisica",null,"1 online resource (230 p.)"]
[null,null,"Classificazione",null,"SCI007000"]
[null,null,"Disciplina",null,"616.994061"]
[null,null,"Soggetti",null,"Antineoplastic agents"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references at the end of each chapters and indexes."]
[null,null,"Nota di contenuto",null,"Title Page; Copyright Page; Contents; Preface; Introduction; Chapter 1 Alkylating Agents; 1.1 bis-Chloroethyl Amines; 1.2 Several Other Chloroethyl Agents; 1.3 Platinum-Based Antineoplastic Agents; 1.4 Miscellaneous Alkylating Agents; References; Chapter 2 Antimetabolites; 2.1 Introduction; 2.2 Folate Antagonists; 2.2.1 Compounds with Glutamate Side Chain; 2.2.2 Compounds Lacking the Glutamate Moiety; 2.2.3 Methoxylated Benzenes; 2.3 Pyrimidines and Purines; 2.3.1 Aglycones; 2.3.2 Saccharide-Linked Compounds; References; Chapter 3 Hormone Blocking Anticancer Drugs; 3.1 Introduction"]
[{"$nulls":4},"3.2 Estrogen Antagonists3.2.1 Estrogen Antagonists; 3.2.2 Aromatase Inhibitors; 3.3 Androgen Antagonists; 3.3.1 Non-steroidal Antian drogens; 3.3.2 Steroid Androgen Antagonists; References; Chapter 4 Topoisomerase Inhibitors; 4.1 Introduction; 4.2 Anthracyclines; 4.3 Anthraquinones and Anthrapyrazoles; 4.3.1 Anthraquinones with Two Aminoalkyl Side Chains; 4.3.2 Anthraquinones with a Fused Pyrazole Ring; 4.3.3 Heterocyclic Anthraquinones; 4.4 Camptothecins; 4.4.1 Compounds from Modified Camptothecin; 4.4.2 Camptothecins by Total Synthesis; 4.5 Miscellaneous Topoisomerase Inhibitors; References"]
[{"$nulls":4},"Chapter 5 Mitotic Inhibitors5.1 Introduction; 5.2 Taxanes; 5.3 Wholly Synthetic Compounds; 5.3.1 Carbocyclic Compounds; 5.3.2 Peptide-Like Inhibitors; 5.3.3 Monocyclic Heterocyclic Inhibitors; 5.3.4 Bicyclic "]
[{"$nulls":4},"5:6 Heterocyclic Inhibitors; 5.3.5 Bicyclic 6:6 Heterocyclic Tubulin Inhibitors; References; Chapter 6 Matrix Metalloproteinase Inhibitors; 6.1 Introduction; 6.2 Hydroxamates; 6.2.1 Agents with an Isobutyl Moiety; 6.2.2 A Thiomorpholine; 6.2.3 Sulfamates; 6.2.4 Miscellaneous Compounds; References; Chapter 7 Histone Deacetylase Inhibitors; 7.1 Introduction; 7.2 Hydroxamates"]
[{"$nulls":4},"7.3 PhenylenediaminesReferences; Chapter 8 Enzyme Inhibitor, Part I, Tyrosine Kinases; 8.1 Introduction; 8.2 Epidermal Growth Factor Inhibitors; 8.3 VEGF; 8.3.1 Fused Ring Compounds; 8.3.2 Linear Arrays; 8.4 SRC Nonreceptor Tyrosine Kinase; 8.5 PDGF; 8.6 EGF; 8.7 Other TKI; 8.7.1 Linear Arrays; 8.7.2 Compounds with Two Fused Rings; 8.8 Janus Kinase Inhibitors; References; Chapter 9 Enzyme Inhibitors: Part II Additional Targets; 9.1 Serine-Threonine Kinase Inhibitors; 9.2 Additional Enzyme Inhibitors; 9.2.1 Farnesyl Transferase Inhibitors; 9.2.2 Cyclin-Dependent Kinase Inhibitors"]
[{"$nulls":4},"9.2.3 Proteasome Inhibitors9.2.4 PARP Inhibitors; 9.2.5 Various Other Enzyme Inhibitors; References; Chapter 10 Miscellaneous Antineoplastic Agents; 10.1 Acyclic; 10.2 Monocyclic; 10.3 Two Linked Rings; 10.4 Rings on a Chain; 10.4.1 Two Rings; 10.4.2 Four and More Rings; 10.5 Fused Rings; 10.5.1 Indoles; 10.5.2 Purine-Like; 10.5.3 Tetralins and a Naphthalene; 10.5.4 Etc.; References; Appendix A; Index of Heterocycle Syntheses; Subject Index; EULA"]
[null,null,null,"Sommario/riassunto","\"Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations\"--"]